Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072282 | 1.00 | KMT2A (0.44) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL12935861 | 1.00 | KMT2A (0.44) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL1636050 | 0.85 | KMT2A (0.45) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL1636052 | 0.85 | KMT2A (0.45) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL14457119 | 0.78 | MMP1 (0.33) | — | |
| SCHEMBL2072284 | 0.75 | — | — | |
| SCHEMBL16510007 | 0.72 | KMT2A (0.55) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL9459023 | 0.68 | KMT2A (0.51) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL11350472 | 0.67 | KMT2A (0.50) | KMT2AMEN1MAPTL3MBTL1LMNA | |
| SCHEMBL11121772 | 0.67 | KMT2A (0.50) | KMT2AMEN1MAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776882-B2 | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| US-7776882-B2 | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007092846-A2 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, PSEN2, BACE1 | KMT2A 684/4885MEN1 1270/4885MAPT 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.